U.S. Online Retail and Ecommerce Stock News

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...

If you are wondering whether NBT Bancorp at around US$40.97 is starting to look interesting, the current share price and fundamentals raise some clear valuation questions worth unpacking. The stock has seen a 0.7% decline over the last week, a 10.4% decline over the past month, and a 1.5% decline year to date, while the 1 year, 3 year, and 5 year returns stand at a 1.9% decline, 34.7%, and 21.3% respectively. Recent attention on regional banks, regulatory capital expectations, and investor...

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...

Intuitive Machines (LUNR) closed FY 2025 with Q4 revenue of US$44.8 million and a basic EPS loss of US$0.17, alongside a net loss of US$19.9 million, while on a trailing 12 month basis revenue was US$210.1 million and EPS stood at a loss of US$0.71 with a net loss of US$83.9 million. Over recent quarters, the company has seen quarterly revenue move from US$62.5 million in Q1 2025 to US$50.3 million in Q2, US$52.4 million in Q3 and US$44.8 million in Q4, with EPS losses ranging between US$0.06...

United States Antimony (NYSE:UAMY) secured a U.S. government contract worth more than $248m for antimony ingots in the past week. The company reported an additional $354m in new antimony agreements, expanding its role in critical mineral supply chains. UAMY announced an acquisition of a tungsten asset in Ontario, targeting domestic tungsten production for North America. The company restarted antimony mining in Montana and is increasing processing capacity with active government...

CONMED (NYSE:CNMD) has exited the gastroenterology market and transferred global distribution rights for certain product lines to Micro-Tech Endoscopy. The company has also appointed Andrew Moller as Interim Chief Financial Officer. For investors watching NYSE:CNMD, these moves come at a time when the share price is around $36.8 and multi year returns have been weak, with the stock down 37.1% over 1 year, 60.8% over 3 years, and 69.5% over 5 years. Stepping away from gastroenterology...

Red Cat Holdings (RCAT) has wrapped up FY 2025 with fourth quarter revenue of about US$26.2 million and a basic EPS loss of US$0.16, alongside trailing twelve month revenue of roughly US$40.7 million and a TTM basic EPS loss of US$0.73. Over the past five reported quarters, the company has seen quarterly revenue range from about US$1.3 million to US$26.2 million. Over the same period, quarterly basic EPS has stayed in loss-making territory between roughly US$0.15 and US$0.33 per share,...

Investors may be wondering whether Wolverine World Wide at US$16.50 still offers value after a strong rebound, or if the easy gains are already behind it. The stock has returned 22.2% over the last year, although the year-to-date return sits at a 9.4% decline, with a 2.4% gain over the last week and an 8.9% decline over the last month. Recent attention on Wolverine World Wide has focused on its brand portfolio, cost structure and balance sheet, as investors weigh how these factors might...

Consolidated Water Co. Ltd. has reported full-year 2025 results, with sales of US$132.07 million versus US$133.97 million a year earlier and net income of US$18.34 million versus US$28.24 million, reflecting softer overall profitability. Despite lower total net income and earnings per share, the company’s earnings per share from continuing operations edged higher, highlighting a relatively stronger performance in its ongoing core businesses. We’ll now examine how the lower full-year net...

Alliant Energy filed a $1b at-the-market equity offering program, signaling a sizeable new capital raise. The program allows the company to issue new shares over time into the open market rather than in a single offering. This move comes as Alliant Energy (NasdaqGS:LNT) continues to invest around large data center customers and recent expansion initiatives. Alliant Energy (NasdaqGS:LNT) is coming off a period where the share price is $71.32 and the stock is up 8.7% year to date and 15.8%...

In its latest quarterly report, CRA International posted an 11.6% year-over-year revenue increase, beating analyst forecasts and marking its eighth consecutive annual revenue record, alongside full-year guidance that also exceeded expectations. This combination of stronger-than-anticipated current performance and higher forward revenue guidance highlights how CRA International is currently converting demand for its consulting expertise into sustained top-line momentum. Next, we'll explore...

Clover Health Investments (NasdaqGS:CLOV) subsidiary Counterpart Health released new data on its digital platform’s impact on flu vaccination rates and acute care events. The evidence links use of Counterpart Health’s tools with higher vaccination uptake and fewer hospitalizations among high risk patients. Clover Health activated real time interoperability for claims data as part of Centers for Medicare & Medicaid Services backed health data exchange efforts. Clover Health Investments,...

ABM Industries (NYSE:ABM) has completed its acquisition of WGNSTAR, a provider of services to semiconductor facilities. The deal expands ABM's footprint in semiconductor fabrication plants and related industrial sites tied to US chip and industrial supply chains. The acquisition will influence ABM's exposure to chip production facilities and data center related demand over time. ABM Industries is known for facility services across commercial, industrial and technology end markets. WGNSTAR...

Accelerant Holdings (ARX) closed FY 2025 with fourth quarter revenue of US$326.9 million and a basic EPS loss of US$0.0027, while the trailing twelve month figures showed revenue of US$912.9 million and a basic EPS loss of US$7.49. Over recent periods, the company has seen quarterly revenue move from US$181.2 million in Q4 2024 to US$163.5 million in Q1 2025, US$204.7 million in Q2 2025, US$217.8 million in Q3 2025 and US$326.9 million in Q4 2025, with EPS shifting from US$10.57 in Q4 2024 to...

EquipmentShare.com (EQPT) just closed FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$0.68. Trailing 12 month revenue came in at US$4.4b with basic EPS of US$0.04 as the business moved into positive net income territory of US$3m over that period. The company has seen quarterly revenue range from US$776.3m in 2024 Q3 to US$1.6b in 2025 Q4, with basic EPS swinging between a loss of US$0.30 in early 2025 and a profit of US$0.68 in the latest quarter. This leaves investors...

SS Innovations International (SSII) drew investor attention after releasing its 2025 results, which combined higher reported revenue with a smaller annual net loss and, at the same time, a going concern warning from auditor BDO LLP. See our latest analysis for SS Innovations International. At a share price of US$5.01, SS Innovations International has seen a 25% 1 month share price return, while the year to date share price return and 1 year total shareholder return remain negative. This hints...

Now profitable: Eva Live reported 82.6% revenue growth to $17M for FY2025 and swung to $8.1M net income, compared to a loss in 2024.

Strive Asset Management (ASST) FY 2025 earnings snapshot Strive Asset Management (ASST) has just wrapped up FY 2025 with Q4 total revenue of about US$1.3 million and a loss per share of US$6.17, alongside a net loss excluding extra items of US$205.6 million, setting a stark backdrop for the latest numbers. Over the past year, revenue has moved from roughly US$0.8 million in Q2 2024 to US$1.3 million in Q4 2025, while trailing twelve month EPS shifted from a US$194.99 loss to a US$12.74 loss...

Tejon Ranch (TRC) has just wrapped up FY 2025 with fourth quarter revenue of US$21.1 million and basic EPS of US$0.06, while the full year on a trailing 12 month basis came in at US$49.6 million of revenue and essentially breakeven EPS around US$0.00. Over recent quarters, the company has seen revenue move from US$8.3 million and basic EPS of a US$0.06 loss in Q2 2025 to US$11.0 million and a US$0.06 loss in Q3 2024, before reaching Q4 2025’s US$21.1 million and US$0.06 EPS. This sets up a...

Accenture (ACN) has reported Q2 2026 results with revenue of US$18.0b and basic EPS of US$2.96, setting the tone for how its consulting and technology services engine is currently translating into top and bottom line performance. The company has seen quarterly revenue move from US$16.7b in Q2 2025 to US$18.0b in Q2 2026, while basic EPS over the same quarters has shifted from US$2.85 to US$2.96, giving investors a clear read on how sales and earnings are tracking together. With a trailing net...

A class action lawsuit has been filed against Soleno Therapeutics (NasdaqCM:SLNO) alleging failures to disclose significant safety concerns in clinical trials for its drug DCCR. The complaint targets the company and certain executives, claiming that undisclosed issues could affect DCCR's commercial prospects and Soleno's reputation. The case focuses on the period around the development and launch preparations of DCCR, Soleno's sole commercial product. Soleno Therapeutics is a biotech...

Aveanna Healthcare Holdings (AVAH) delivers full year 2025 results Aveanna Healthcare Holdings (AVAH) has wrapped up FY 2025 with fourth quarter revenue of US$662.5 million, basic EPS of US$0.85 and net income excluding extraordinary items of US$178.8 million. This frames a year where trailing twelve month revenue reached about US$2.4 billion and basic EPS was US$1.11. Over recent periods the company has seen revenue move from US$519.9 million in Q4 FY 2024 to US$662.5 million in Q4 FY 2025,...

Yiren Digital’s FY 2025 Results Put Margins Under the Microscope Yiren Digital (NYSE:YRD) has just closed out FY 2025 with fourth quarter revenue of C¥957.6 million and a loss per share of C¥10.12, as net income excluding extra items came in at a loss of C¥882.2 million against a C¥2.03 share price. The company has seen quarterly revenue range from C¥1,652.1 million in Q2 2025 to C¥1,452.2 million in Q4 2024. Basic EPS moved from a profit of C¥3.84 in Q4 2024 to a loss in the latest quarter,...